Back
Eaton Vance Enhanced Equity Income Fund II Vs. Halozyme Therapeutics Industry Stock Comparison
Buy
65
EOS
Eaton Vance Enhanced Equity Income Fund II
Last Price:
22.73
Seasonality Move:
2.01%
Sell
39
HALO
Halozyme Therapeutics
Last Price:
45.65
Seasonality Move:
17.03%
Buy
65
Eaton Vance Enhanced Equity Income Fund II (EOS)
is a Buy
Is Eaton Vance Enhanced Equity Income Fund II a Buy, Sell or Hold?
- The current Eaton Vance Enhanced Equity Income Fund II [EOS] share price is $22.74. The Score for EOS is 65, which is 30% above its historic median score of 50, and infers lower risk than normal.
- EOS is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
39
Halozyme Therapeutics (HALO)
is a Sell
Is Halozyme Therapeutics a Buy, Sell or Hold?
- The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
- HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
EOS Stock Price Chart
What is Eaton Vance Enhanced Equity Income Fund II's stock price today?
-
The Eaton Vance Enhanced Equity Income Fund II share price today is $22.74
The current trend is moderately bullish and EOS is experiencing slight buying pressure.
HALO Stock Price Chart
What is Halozyme Therapeutics's stock price today?
-
The Halozyme Therapeutics share price today is $45.65
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.
EOS Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.27 | Buy |
| Relative Strength Index (14 RSI): | 57.18 | Buy |
| Chaikin Money Flow: | 23726 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (22.11 - 22.85) | Buy |
| Bollinger Bands (100): | (21.01 - 22.39) | Buy |
HALO Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.02 | Sell |
| Relative Strength Index (14 RSI): | 30.2 | Sell |
| Chaikin Money Flow: | -7140517 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (49.94 - 58.56) | Sell |
| Bollinger Bands (100): | (52.16 - 60.38) | Sell |
EOS Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 22.97 | Sell |
| 20-day SMA: | 22.56 | Buy |
| 50-day SMA: | 22.04 | Buy |
| 200-day SMA: | 21.02 | Buy |
| 8-day EMA: | 22.83 | Sell |
| 20-day EMA: | 22.59 | Buy |
| 50-day EMA: | 22.16 | Buy |
| 200-day EMA: | 20.97 | Buy |
HALO Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 57.53 | Sell |
| 20-day SMA: | 54.48 | Sell |
| 50-day SMA: | 56.18 | Sell |
| 200-day SMA: | 48.93 | Sell |
| 8-day EMA: | 55 | Sell |
| 20-day EMA: | 55.41 | Sell |
| 50-day EMA: | 55.64 | Sell |
| 200-day EMA: | 50.73 | Sell |
Eaton Vance Enhanced Equity Income Fund II Earnings Growth & EOS Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Halozyme Therapeutics Earnings Growth & HALO Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.
Eaton Vance Enhanced Equity Income Fund II Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Halozyme Therapeutics Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||